Open Access

Identification of key candidate tumor biomarkers in non‑small‑cell lung cancer by in silico analysis

  • Authors:
    • Weiping Chen
    • Song Zhu
    • Yifei Zhang
    • Jinghua Xiao
    • Dongbo Tian
  • View Affiliations

  • Published online on: December 2, 2019     https://doi.org/10.3892/ol.2019.11169
  • Pages: 1008-1016
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Lung cancer is a common malignancy worldwide. The aim of the present study was to investigate differentially expressed genes (DEGs) between non‑small‑cell lung cancer (NSCLC) and normal lung tissue, and to reveal the potential molecular mechanism underlying NSCLC. The Gene Expression Omnibus database was used to obtain three gene expression profiles (GSE18842, GSE30219 and GSE33532). DEGs were obtained by GEO2R. Gene Ontology and pathway enrichment analyses were performed for DEGs in the Database for Annotation, Visualization and Integrated Discovery. A protein‑protein interaction (PPI) network of DEGs was constructed and analyzed using the Search Tool for the Retrieval of Interacting Genes/Proteins database and Cytoscape software. A survival analysis was performed and protein expression levels of DEGs in human NSCLC were analyzed in order to determine clinical significance. A total of 764 DEGs were identified, consisting of 428 upregulated and 336 downregulated genes in NSCLC tissues compared with normal lung tissues, which were enriched in the ‘cell cycle’, ‘cell adhesion molecules’, ‘p53 signaling pathway’, ‘DNA replication’ and ‘tight junction’. A PPI network of DEGs consisting of 51 nodes and 192 edges was constructed. The top 10 genes were identified as hub genes from the PPI network. High expression of 4 of the 10 hub genes was associated with worse overall survival rate in patients with NSCLC, including CDK1, PLK1, RAD51 and RFC4. In conclusion, the present study aids in improving the current understanding of aberrant gene expression between NSCLC tissues and normal lung tissues underlying tumorgenesis in NSCLC. Identified hub genes can be used as a tumor marker for diagnosis and prognosis or as a drug therapy target in NSCLC.

Related Articles

Journal Cover

January 2020
Volume 19 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chen, W., Zhu, S., Zhang, Y., Xiao, J., & Tian, D. (2020). Identification of key candidate tumor biomarkers in non‑small‑cell lung cancer by in silico analysis. Oncology Letters, 19, 1008-1016. https://doi.org/10.3892/ol.2019.11169
MLA
Chen, W., Zhu, S., Zhang, Y., Xiao, J., Tian, D."Identification of key candidate tumor biomarkers in non‑small‑cell lung cancer by in silico analysis". Oncology Letters 19.1 (2020): 1008-1016.
Chicago
Chen, W., Zhu, S., Zhang, Y., Xiao, J., Tian, D."Identification of key candidate tumor biomarkers in non‑small‑cell lung cancer by in silico analysis". Oncology Letters 19, no. 1 (2020): 1008-1016. https://doi.org/10.3892/ol.2019.11169